The TDM One Trial in Lung Cancer

There was a lot of skepticism at the time. This was 2014 that many her two experts who really spent their lifetime doing tyrosine kinase inhibitor, cell signaling and lock and key approach. So it came as a surprise when the TDM One trial was positive. And we then were able to guide the registration trial of Trastism and Duroxstikin which was first developed for her to amplify and then her to low breast cancer. It's all largely due to protein expression, not mutations. But because of this internalization concept that we had published and shown subsequently, we doubled down on that in lung cancer. We're talking thousands and thousands of patients every single year just